All In Biotech

Drug Trial Radar · NCT01438489

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Oct 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 626 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

626

Actual

Start

Jan 2012

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of MEDI-546 compared to placebo in subjects with chronic, moderately-to-severely active systemic lupus erythematosus (SLE) with an inadequate response to standard of care treatment for SLE.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Anifrolumab 300 mgBiological

    Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

  • Anifrolumab 1000 mgBiological

    Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.

  • PlaceboOther

    Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169Time frame: Day 169
  2. Percentage of Type I Interferon (IFN) Test High Participants Achieving an Systemic Lupus Erythematosus Responder Index (SRI) (4) Response With Oral Corticosteroids (OCS) Tapering at Day 169Time frame: Day 169

Locations

79 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    La Jolla, California

  • Research Site

    La Palma, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Palm Desert, California

  • Research Site

    San Leandro, California

  • Research Site

    Upland, California

  • Research Site

    Miami, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Palm Harbor, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Decatur, Georgia

  • Research Site

    Stockbridge, Georgia

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Edmond, Oklahoma

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Memphis, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Seattle, Washington

  • Research Site

    Spokane, Washington

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Barranquilla, Colombia

  • Research Site

    Bogotá, Colombia

  • Research Site

    Bucaramanga, Colombia

  • Research Site

    Chía, Colombia

  • Research Site

    Medellín, Colombia

  • Research Site

    Brno, Czechia

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.